Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Insmed Inc Market Cap
The Insmed Inc (INSM) share price is expected to increase by 42.07% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered INSM. Price targets range from $35.00 at the low end to $55.00 at the high end. The current analyst consensus for INSM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Insmed Inc has a total of 6 Wall St Analyst ratings. There are 6 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Insmed Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| joseph schwartz Leerink Partners | Buy | $50.0 | reiterated | Feb 11, 2024 |
| tiago fauth Wells Fargo | Buy | $55.0 | maintained | Feb 1, 2024 |
| graig suvannavejh Mizuho Securities | Buy | $35.0 | reiterated | Jan 16, 2024 |
| ritu baral TD Cowen | Buy | $45.004 | maintained | Jan 8, 2024 |
| jeffrey hung Morgan Stanley | Buy | $40.0 | maintained | Jan 5, 2024 |
| jason zemansky Bank of America Securities | Buy | $37.0 | reiterated | Jan 5, 2024 |
| leon wang Barclays | Buy | $37.0 | maintained | Jan 5, 2024 |
| jessica fye J.P. Morgan | Buy | $36.0 | initiatedcoverage | Nov 20, 2023 |
| andrew fein H.C. Wainwright | Buy | $52.0 | reiterated | Oct 27, 2023 |
| jennifer kim Cantor Fitzgerald | Buy | $54.0 | reiterated | Oct 26, 2023 |
| liisa bayko Evercore ISI | Buy | $42.0 | maintained | Sep 7, 2023 |
| vamil divan Guggenheim | Buy | $52.0 | maintained | Sep 5, 2023 |
| stephen willey Stifel Nicolaus | Buy | $35.0 | maintained | Aug 4, 2023 |
| judah frommer Credit Suisse | Buy | $46.0 | reiterated | Feb 24, 2023 |
| andrea tan Goldman Sachs | Buy | $39.0 | maintained | Jan 9, 2023 |
| carter gould Barclays | Buy | $37.0 | initiatedcoverage | Dec 7, 2022 |
| matthew harrison Morgan Stanley | Buy | $41.0 | maintained | Jul 15, 2022 |
| anita dushyanth Berenberg Bank | Buy | $46.0 | maintained | May 7, 2022 |
| adam walsh Stifel Nicolaus | Buy | $45.0 | maintained | Mar 17, 2020 |
| liav abraham Citigroup | Hold | $30.0 | maintained | Apr 3, 2019 |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
When did it IPO
0
Staff Count
736
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. William H. Lewis J.D., M.B.A.
Market Cap
$4.22B
In 2023, INSM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that INSM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
POWI-USD
$73.35
ACT-USD
$26.7
AVT-USD
$46.44
MRTX-USD
$58.7
FRPT-USD
$89.26
ACAD-USD
$24.85
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
